Prasugrel Hydrochloride
FDA-approved product (tablet, oral), marketed as Effient, Prasugrel, Prasugrel Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute coronary syndrome
- Hemorrhage
- Intermediate coronary syndrome
- Myocardial infarction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Platelet aggregation inhibitors excl. heparin
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Prasugrel Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Prasugrel/Clopidogrel Maintenance Dose Washout Study
NCT01014624 · start 2010-02
Registered record
- Registry ID
- NCT01014624
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-02
- Completion
- 2010-06
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionPrasugrel; ClopidogrelPhasePhase 4Registry statusCompletedCYPRESS - CYPHER for Evaluating Sustained Safety
NCT00954707 · start 2009-08
Registered record
- Registry ID
- NCT00954707
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & Aspirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2009-08
- Completion
- 2016-03
- Enrolment
- 2,509
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionClopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & AspirinPhasePhase 4Registry statusUnknownA Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
NCT00699998 · start 2008-06
Registered record
- Registry ID
- NCT00699998
- Conditions
- Acute Coronary Syndrome
- Interventions
- Clopidogrel; Prasugrel; Commercially-available Aspirin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2012-04
- Enrolment
- 9,326
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionClopidogrel; Prasugrel; Commercially-available AspirinPhasePhase 3Registry statusCompletedThird Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
NCT00642174 · start 2008-04
Registered record
- Registry ID
- NCT00642174
- Conditions
- Diabetes Mellitus; Coronary Artery Disease
- Interventions
- prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-04
- Completion
- 2009-01
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus; Coronary Artery DiseaseInterventionprasugrel; ClopidogrelPhasePhase 2Registry statusCompletedThe Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
NCT00385944 · start 2007-03
Registered record
- Registry ID
- NCT00385944
- Conditions
- Acute Coronary Syndrome
- Interventions
- Prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2007-10
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionPrasugrel; ClopidogrelPhasePhase 2Registry statusCompleted